| Christy Dawn South, MD | |
|
2490 S Woodworth Loop Ste 301, Palmer, AK 99645-7407 | |
| (907) 746-7747 | |
| (907) 746-7731 |
| Full Name | Christy Dawn South |
|---|---|
| Gender | Female |
| Speciality | Obstetrics/gynecology |
| Experience | 21 Years |
| Location | 2490 S Woodworth Loop Ste 301, Palmer, Alaska |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1154478584 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mat-su Regional Medical Center | Palmer, AK | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mat-su Valley Iii Llc | 5496941502 | 30 |
News Archive
Acupuncture, when used as a complementary or adjuvant therapy for in vitro fertilization (IVF), may be beneficial depending on the baseline pregnancy rates of a fertility clinic, according to research from the University of Maryland School of Medicine. The analysis from the University of Maryland Center for Integrative Medicine is published in the June 27 online edition of the journal Human Reproduction Update.
In a new study published in the December 1 issue of Clinical Infectious Diseases, currently available online, researchers tracked the developing drug resistance of one particular strain of Mycobacterium tuberculosis over 12 years.
Antares Pharma, Inc. announced today that it has completed enrollment in the double-blind portion of the Company's Phase 3 clinical trial of Anturol™, its transdermal oxybutynin ATD™ gel for the treatment of overactive bladder (OAB). Top line data from this pivotal trial, which is being conducted under a Special Protocol Assessment (SPA) from the U.S. Food and Drug Administration (FDA), is expected in the third quarter of this year.
ImmunoCellular Therapeutics, Ltd., a biotechnology company that is developing immune based therapies for the treatment of various forms of cancer, announced today that the Company has entered into a sponsored research agreement and an option agreement with The University of Pennsylvania to support process development and manufacturing in a planned Phase II clinical trial of ICT-107, the Company's dendritic-cell based cancer vaccine product candidate for the treatment of glioblastoma multiforme.
A wearable sensor printed on microbial nanocellulose, a natural polymer, has been created in Brazil by researchers at the University of São Paulo in São Carlos in collaboration with colleagues at São Paulo State University in Araraquara, the University of Araraquara, the University of Campinas, and the Brazilian National Nanotechnology Laboratory.
› Verified 7 days ago
| Entity Name | Mat-su Valley Iii Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366752560 PECOS PAC ID: 5496941502 Enrollment ID: O20101130001385 |
News Archive
Acupuncture, when used as a complementary or adjuvant therapy for in vitro fertilization (IVF), may be beneficial depending on the baseline pregnancy rates of a fertility clinic, according to research from the University of Maryland School of Medicine. The analysis from the University of Maryland Center for Integrative Medicine is published in the June 27 online edition of the journal Human Reproduction Update.
In a new study published in the December 1 issue of Clinical Infectious Diseases, currently available online, researchers tracked the developing drug resistance of one particular strain of Mycobacterium tuberculosis over 12 years.
Antares Pharma, Inc. announced today that it has completed enrollment in the double-blind portion of the Company's Phase 3 clinical trial of Anturol™, its transdermal oxybutynin ATD™ gel for the treatment of overactive bladder (OAB). Top line data from this pivotal trial, which is being conducted under a Special Protocol Assessment (SPA) from the U.S. Food and Drug Administration (FDA), is expected in the third quarter of this year.
ImmunoCellular Therapeutics, Ltd., a biotechnology company that is developing immune based therapies for the treatment of various forms of cancer, announced today that the Company has entered into a sponsored research agreement and an option agreement with The University of Pennsylvania to support process development and manufacturing in a planned Phase II clinical trial of ICT-107, the Company's dendritic-cell based cancer vaccine product candidate for the treatment of glioblastoma multiforme.
A wearable sensor printed on microbial nanocellulose, a natural polymer, has been created in Brazil by researchers at the University of São Paulo in São Carlos in collaboration with colleagues at São Paulo State University in Araraquara, the University of Araraquara, the University of Campinas, and the Brazilian National Nanotechnology Laboratory.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Christy Dawn South, MD 2490 S Woodworth Loop Ste 301, Palmer, AK 99645-7407 Ph: (907) 746-7747 | Christy Dawn South, MD 2490 S Woodworth Loop Ste 301, Palmer, AK 99645-7407 Ph: (907) 746-7747 |
News Archive
Acupuncture, when used as a complementary or adjuvant therapy for in vitro fertilization (IVF), may be beneficial depending on the baseline pregnancy rates of a fertility clinic, according to research from the University of Maryland School of Medicine. The analysis from the University of Maryland Center for Integrative Medicine is published in the June 27 online edition of the journal Human Reproduction Update.
In a new study published in the December 1 issue of Clinical Infectious Diseases, currently available online, researchers tracked the developing drug resistance of one particular strain of Mycobacterium tuberculosis over 12 years.
Antares Pharma, Inc. announced today that it has completed enrollment in the double-blind portion of the Company's Phase 3 clinical trial of Anturol™, its transdermal oxybutynin ATD™ gel for the treatment of overactive bladder (OAB). Top line data from this pivotal trial, which is being conducted under a Special Protocol Assessment (SPA) from the U.S. Food and Drug Administration (FDA), is expected in the third quarter of this year.
ImmunoCellular Therapeutics, Ltd., a biotechnology company that is developing immune based therapies for the treatment of various forms of cancer, announced today that the Company has entered into a sponsored research agreement and an option agreement with The University of Pennsylvania to support process development and manufacturing in a planned Phase II clinical trial of ICT-107, the Company's dendritic-cell based cancer vaccine product candidate for the treatment of glioblastoma multiforme.
A wearable sensor printed on microbial nanocellulose, a natural polymer, has been created in Brazil by researchers at the University of São Paulo in São Carlos in collaboration with colleagues at São Paulo State University in Araraquara, the University of Araraquara, the University of Campinas, and the Brazilian National Nanotechnology Laboratory.
› Verified 7 days ago
Dr. Cassandra Rae Cook, D.O. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: Mat-su Women's Health Specialists, 2490 S. Woodworth Loop Suite 301, Palmer, AK 99645 Phone: 907-746-7747 Fax: 907-746-7731 | |
Dr. John David Houghton, DO Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 2490 S Woodworth Loop Ste 301, Palmer, AK 99645 Phone: 907-746-7747 Fax: 907-746-7740 | |
Susan M Lemagie, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 425 E Dahlia Ave, Suite J, Palmer, AK 99645 Phone: 907-745-8379 |